New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including ...

RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a ...

Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

Eisai Co. (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, U.S. brand name: LEQEMBI IQLIKTM, ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

AJMC: Osimertinib is an oral drug, whereas amivantamab is an intravenous formulation. Given those differences in delivery ...

Both Halozyme and Elektrofi have partnered with several Big Pharma companies to provide drug delivery technologies.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.